Information Provided By: 
Fly News Breaks for February 20, 2018
SHPG
Feb 20, 2018 | 06:40 EDT
JPMorgan analyst James Gordon yesterday downgraded Shire to Neutral while lowering his price target for the shares to $150 from $200. The analyst sees few catalysts in 2018 and 2019 beyond a potential NeuroScience spinoff, which he does not see as creating fundamental value. Further, he believes the "Haemophilia overhang" will likely to weigh on Shire's Rare Disease business over the next two years.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
